Endocrinology

Building Your Care Team and Managing Family Genetics

At a Glance

Familial hyperaldosteronism type III is best managed by a coordinated endocrine, blood-pressure, genetics, and surgical team. Genetic counseling and testing for parents, siblings, and children can identify risk early and support informed reproductive choices.

Managing a rare condition like FH-III requires a team approach that looks beyond the present moment and helps safeguard your family’s future. Because Familial Hyperaldosteronism Type III (FH-III) is a rare and complex condition, its management requires more than a single doctor. It involves a specialized multidisciplinary team capable of managing high-risk hypertension, pediatric endocrine needs, and potentially life-altering surgery ^[1]^[2].

Building Your Care Team

It is recommended that your care be coordinated by a team with expertise across several fields ^[1]. This team typically includes:

Specialized Endocrinologist: Look for a doctor who specifically treats primary aldosteronism. If the patient is a child, a pediatric endocrinologist is essential ^[1]^[3].
Hypertension Specialist or Nephrologist: These experts focus on protecting the kidneys and heart from the strain of extreme high blood pressure ^[1].
Clinical Geneticist: A genetics team helps interpret the KCNJ5 results and guides testing for other family members ^[4].
High-Volume Endocrine Surgeon: If surgery is being considered, the surgeon should be part of a “high-volume” center. For adults, some guidelines suggest a minimum of six adrenal surgeries per year as a quality signal, though it’s important to note this volume threshold is from adult guidelines and not automatically validated for pediatric FH-III. Pediatric centers should be evaluated based on having a multidisciplinary team experienced with pediatric endocrine surgery, adrenal insufficiency, and long-term endocrine follow-up ^[5]^[6].

Vetting Your Surgeon

When discussing bilateral adrenalectomy (removing both glands), you are considering a permanent change. Ask your surgical team:

Do you have an experienced robotic or laparoscopic team for pediatric patients? ^[6]
How will you manage the perioperative steroid coverage (stress-dose steroids) during the surgery? ^[7]^[8]
Does the hospital have a pediatric intensive care unit (PICU) for recovery? ^[9]

Transition of Care

Ensure there is a clear transition plan for adolescents moving to adult care, addressing changes in MRA choices, adrenal-replacement dosing, and pregnancy-management considerations.

Family Genetics and Screening

FH-III is an autosomal dominant condition ^[2].

Cascade Screening

When one person is diagnosed with FH-III, it is standard practice to offer cascade screening (paired with genetic counseling) to their first-degree relatives (parents, siblings, and children) ^[10].

The Transmission Risk: This means if a parent carries a heterozygous pathogenic variant, each child has a 50% chance of inheriting it ^[11].
Variable Severity: It is important to note that penetrance and expressivity can vary, and some carriers may have subtle or no recognized manifestations. One person may have severe childhood hypertension, while another with the same mutation may have milder symptoms or only low potassium ^[2]^[12].
De Novo Mutations: In some cases, the mutation is “de novo,” meaning it started with the patient and was not inherited from a parent ^[13].

Reproductive Options and Future Planning

For individuals with FH-III who are planning a family, modern medicine offers optional paths for those who wish to consider them.

Preimplantation Genetic Testing (PGT-M): This option requires a confirmed familial pathogenic variant and the use of IVF (In Vitro Fertilization) to test embryos for the specific KCNJ5 mutation before they are implanted ^[14]^[15].
Prenatal Diagnosis: If a pregnancy has already begun, tests like chorionic villus sampling (CVS) or amniocentesis can determine if the fetus has inherited the mutation. Prenatal diagnosis involves procedure-specific risks and ethical considerations ^[16]^[17].
Pre-conception Counseling: Meeting with a reproductive geneticist allows you to discuss the medical, psychological, and ethical aspects of these choices in a supportive environment ^[18]^[19].

A genetic diagnosis is not just a label; it is a tool that allows your family to seek early screening, protect your health, and make informed choices for the next generation ^[4]^[1].

Common questions in this guide

Which specialists should be involved in FH-III care?

Care is usually coordinated by an endocrinologist who treats primary aldosteronism, with pediatric endocrinology for children. A hypertension specialist or nephrologist, clinical geneticist, and experienced endocrine surgeon may also be involved, especially when surgery is being considered.

How is familial hyperaldosteronism type III passed through a family?

FH-III is usually inherited in an autosomal dominant pattern. If a parent has one pathogenic KCNJ5 variant, each child has a 50% chance of inheriting it, although the severity of the condition can differ between relatives.

Should parents, siblings, and children of someone with FH-III get tested?

First-degree relatives should be offered genetic counseling and testing for the known family variant. Testing can identify relatives who need blood-pressure and aldosterone evaluation, even if they currently have no noticeable symptoms.

How should I choose a surgeon for bilateral adrenalectomy?

Look for a center with experience in endocrine surgery and, for children, pediatric adrenal surgery and long-term hormone care. Ask about the surgeon's experience with KCNJ5-related cases, minimally invasive surgery, stress-dose steroids, intensive care support, and lifelong adrenal hormone replacement if both glands are removed.

What reproductive options are available for people with FH-III?

A reproductive geneticist can discuss preimplantation genetic testing for a specific KCNJ5 variant with in vitro fertilization. During pregnancy, chorionic villus sampling or amniocentesis may provide prenatal diagnosis; each option has medical, psychological, ethical, and procedure-related considerations.

What should be included in the transition from pediatric to adult FH-III care?

The transition plan should identify the adult endocrinology and hypertension teams and explain how medications, adrenal hormone replacement, and emergency care will be managed. It should also address pregnancy planning and ensure that the new team understands the patient's genetic and surgical history.

Get notified when new evidence is published on Familial hyperaldosteronism type III.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

FH-III care is best coordinated by endocrinology, hypertension or nephrology, clinical genetics, and endocrine surgery specialists, with pediatric expertise when needed.
Parents, siblings, and children should be offered genetic counseling and testing, and each child of a heterozygous carrier has a 50% chance of inheriting the variant.
FH-III can vary widely among relatives, with some carriers having mild or unrecognized manifestations and some cases arising from a new mutation.
People considering bilateral adrenalectomy should ask about pediatric experience, stress-dose steroids, intensive care support, and lifelong adrenal hormone replacement.
Reproductive genetic counseling can explain PGT-M with IVF, prenatal diagnosis, and the medical and ethical considerations of each option.

References (19)

1
Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline.
Mulatero P, Scholl UI, Fardella CE, et al.
European journal of endocrinology 2024; (190(4)):G1-G14 doi:10.1093/ejendo/lvae041.
PMID: 38571460
2
Familial hyperaldosteronism type III.
Monticone S, Tetti M, Burrello J, et al.
Journal of human hypertension 2017; (31(12)):776-781 doi:10.1038/jhh.2017.34.
PMID: 28447626
3
Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism.
Araujo-Castro M, Parra P, Martín Rojas-Marcos P, et al.
Frontiers in endocrinology 2024; (15()):1336306 doi:10.3389/fendo.2024.1336306.
PMID: 38495792
4
Approaches to Genetic Screening in Cardiomyopathies: Practical Guidance for Clinicians.
Kontorovich AR
JACC. Heart failure 2023; (11(2)):133-142 doi:10.1016/j.jchf.2022.11.025.
PMID: 36754525
5
Volume-outcome relationship for adrenalectomy: analysis of an administrative dataset for the Getting It Right First Time Programme.
Gray WK, Day J, Briggs TWR, et al.
The British journal of surgery 2021; (108(9)):1112-1119 doi:10.1093/bjs/znab142.
PMID: 33990837
6
Synchronous bilateral adrenalectomy for ACTH-independent Cushing's syndrome in children: multidisciplinary management.
Tulelli B, Besançon A, Stoupa A, et al.
European journal of endocrinology 2024; (191(6)):646-657 doi:10.1093/ejendo/lvae158.
PMID: 39676528
7
Laparoscopic Bilateral Adrenalectomy in a Young Female Patient with Recurrent Cushing's Disease.
Kanchana WGP, Kumarathunga PADM, Shakthilingham G, et al.
Case reports in endocrinology 2021; (2021()):6632436 doi:10.1155/2021/6632436.
PMID: 33628530
8
Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: Guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK.
Woodcock T, Barker P, Daniel S, et al.
Anaesthesia 2020; (75(5)):654-663 doi:10.1111/anae.14963.
PMID: 32017012
9
MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion.
Young J, Haissaguerre M, Viera-Pinto O, et al.
European journal of endocrinology 2020; (182(4)):R29-R58.
PMID: 31999619
10
Genetic testing for inherited arrhythmia syndromes and cardiomyopathies: results of the European Heart Rhythm Association survey.
Zeljkovic I, Gauthey A, Manninger M, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2024; (26(9)) doi:10.1093/europace/euae216.
PMID: 39148456
11
Preimplantation Genetic Diagnosis Counseling in Autosomal Dominant Polycystic Kidney Disease.
Murphy EL, Droher ML, DiMaio MS, Dahl NK
American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (72(6)):866-872 doi:10.1053/j.ajkd.2018.01.048.
PMID: 29606500
12
A NOVEL KCNJ5 GENE MUTATION ASSOCIATED WITH FAMILIAL ALDOSTERONISM TYPE III WITHOUT HYPERTENSION.
Zhou MY, Yu SQ, Zhu SJ, et al.
Georgian medical news 2026; 259-265.
PMID: 42830061
13
Familial hyperaldosteronism type III a novel case and review of literature.
Pons Fernández N, Moreno F, Morata J, et al.
Reviews in endocrine & metabolic disorders 2019; (20(1)):27-36 doi:10.1007/s11154-018-9481-0.
PMID: 30569443
14
Preimplantation Genetic Testing for Monogenic Disorders.
De Rycke M, Berckmoes V
Genes 2020; (11(8)) doi:10.3390/genes11080871.
PMID: 32752000
15
Genetic counseling for pre-implantation genetic testing of monogenic disorders (PGT-M).
Parikh F, Athalye A, Madon P, et al.
Frontiers in reproductive health 2023; (5()):1213546 doi:10.3389/frph.2023.1213546.
PMID: 38162012
16
Prenatal diagnosis and preimplantation genetics testing of 3M syndrome in a Chinese family with novel biallelic variants of CUL7.
Wang X, He Y, Wang X, et al.
Molecular genetics & genomic medicine 2024; (12(1)):e2284 doi:10.1002/mgg3.2284.
PMID: 37877343
17
Identification of a KRT9 gene variant and preimplantation genetic diagnosis in a Chinese family with KRT9-palmoplantar epidermal differentiation disorder.
Lin D, Lin N, Zhou Y, et al.
Hereditas 2025; (162(1)):183 doi:10.1186/s41065-025-00552-y.
PMID: 40993822
18
Regulating Preimplantation Genetic Testing across the World: A Comparison of International Policy and Ethical Perspectives.
Ginoza MEC, Isasi R
Cold Spring Harbor perspectives in medicine 2020; (10(5)) doi:10.1101/cshperspect.a036681.
PMID: 31506325
19
ADPKD, pregnancy and preimplantation selection: clinical and bioethical considerations.
Zarantonello D, Piccoli GB, Zuccarello D, et al.
Journal of nephrology 2026; (39(3)):455-467 doi:10.1093/joneph/aajag051.
PMID: 42154631

This page explains care coordination, genetic screening, and reproductive planning for FH-III for informational purposes only and does not constitute medical advice. Your endocrinology, genetics, and surgical teams should guide decisions about testing and treatment.